CHRS - יחס מהיר Coherus BioSciences Inc.

Coherus Biosciences (CHRS) relies on a patent-protected portfolio of anti-tumor agents and biosimilars, where physician recognition ensures a steady stream of profit. This price action chart on GURU.Markets, where the indicator stands at 1.65, confirms the role of biosimilars as the primary cash generator despite declining profitability. However, fierce pricing competition and the high cost of testing new treatment regimens create significant financial risks.

Stable demand for oncology drugs from Coherus Biosciences (CHRS) provides the business with high macro-resilience. The current value of 1.65 reflects the company's ability to settle short-term obligations using only cash and accounts receivable, excluding illiquid inventories. It is critical for investors to identify the balance between capital safety and capital efficiency. The acid-test ratio trend on the GURU.Markets platform clearly demonstrates the asset's real financial strength.